Navigation Links
Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations
Date:2/16/2010

LAWRENCEVILLE, N.J., Feb. 16 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Wayne S. Mulcahy, Ph.D., has joined the company as Vice President, Clinical Operations. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan diseases.

The company's comprehensive portfolio of well-established specialty pharmaceuticals targets cardiovascular (Mephyton®, Edecrin®, Sodium Edecrin®), metabolic (Cuprimine®, Syprine®, Demser®) and ophthalmic (Lacrisert® and the Timoptic® product line) diseases.

With more than 30 years of experience in clinical operations, Dr. Mulcahy has been responsible for the development and management of clinical programs across a range of therapeutic classes, including cardiovascular and CNS disorders, experience which is highly relevant to the clinical programs he will lead for Aton.

"Dr. Mulcahy's extensive scientific, clinical and regulatory background will provide exemplary leadership for Aton's burgeoning pipeline of development programs," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "His technical acumen and strong track record of NDA submissions will help Aton fulfill its mission of bringing innovative and medically necessary medications to patients in need around the world."

Prior to joining Aton, Dr. Mulcahy served as Vice President of Research and Development at Alita Pharmaceuticals, as Vice President of Clinical Operations at the Duramed Research subsidiary of Barr Pharmaceuticals and as Senior Director of Scientific and Regulatory Affairs at Teva Pharmaceuticals North America. He began his pharmaceutical career at Merck Research Laboratories where he was awarded a Doctoral Study Fellowship. Dr. Mulcahy earned his Ph.D. in pharmacology from Temple University School of Medicine, an M.S. from Drexel University and his B.A. from Arcadia University.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.

SOURCE Aton Pharma, Inc.

RELATED LINKS
http://www.atonrx.com

'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VPCI Pioneers Virtual GMP Consulting for FDA Pharmaceutical Manufacturers
2. International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain
3. Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R)
4. Bioniche Pharma Acquires Seven New Products From GeneraMedix Inc.
5. International Merchant Advisors, Inc. Offers to Invest in Pharmaceutical Chain
6. Endo Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 22, 2010
7. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
8. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
9. Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds
10. Berkery Noyes Releases 2009 Pharma and Healthcare Information Merger & Acquisition Trends
11. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... -- Provides understanding and access to the anemia ... worlds leading healthcare companies. Download the full ... Anemia Partnering Terms and Agreements since 2010 report ... agreements entered into by the world,s leading healthcare ... - Top deals by value - ...
(Date:2/20/2017)... Feb. 20, 2017 This report analyzes the worldwide ... market is analyzed by the following Segments: Biologic Meshes, and ... US, Canada , Japan ... , and Rest of World. Read the ... forecasts are provided for the period 2015 through 2022. Also, ...
(Date:2/20/2017)... , Feb. 20, 2017  Henry Schein, ... health care products and services to office-based ... announced that it has entered into an ... (SAS), a leading U.S. distributor of anesthesia ... anesthesiologists, and periodontists. SAS offers controlled and ...
Breaking Medicine Technology:
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... Braun Industries ... JEMS Conference & Exposition, the event will take place February 23-25, 2017 at the ... will be in Booth #909 with three new ambulances on display. ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 — 1:30 ... to reduce their regulatory burden? Pay dividends in enhanced and predictable product ...
(Date:2/18/2017)... ... ... Park Cities Pet Sitter President, Joette White, has been featured on Episode ... The episode, which was posted this week, features a 30-minute interview of White by ... Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s Business of ...
(Date:2/17/2017)... ... 2017 , ... While EHR data has revolutionized the nursing ... workstation designed to reduce nursing fatigue while enhancing productivity. Based on field experience ... lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. , Nurses ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... , **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 ... questions manufacturers should be asking before selecting an FDA approval pathway? , ...
Breaking Medicine News(10 mins):